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Abstract 
Background: There is a large body of experimental evidence suggesting that omega-3 (n-3) polyunsaturated fatty 
acids (PUFAs) are capable of modulating immune function. Some studies have shown that these PUFAs might have 
a beneficial effect in patients suffering form multiple sclerosis (MS), a chronic inflammatory demyelinating disease of 
the central nervous system (CNS). This could be due to increased n-3 PUFA-derived anti-inflammatory lipid media-
tors. In the present study we tested the effect of an endogenously increased n-3 PUFA status on cuprizone-induced 
CNS demyelination and remyelination in fat-1 mice versus their wild-type (wt) littermates. Fat-1 mice express an n-3 
desaturase, which allows them to convert n-6 PUFAs into n-3 PUFAs.
Results: CNS lipid profiles in fat-1 mice showed a significant increase of eicosapentaenoic acid (EPA) levels but similar 
docosahexaenoic acid levels compared to wt littermates. This was also reflected in significantly higher levels of mono-
hydroxy EPA metabolites such as 18-hydroxyeicosapentaenoic acid (18-HEPE) in fat-1 brain tissue. Feeding fat-1 mice 
and wt littermates 0.2% cuprizone for 5 weeks caused a similar degree of CNS demyelination in both groups; remyeli-
nation was increased in the fat-1 group after a recovery period of 2 weeks. However, at p = 0.07 this difference missed 
statistical significance.
Conclusions: These results indicate that n-3 PUFAs might have a role in promotion of remyelination after toxic injury 
to CNS oligodendrocytes. This might occur either via modulation of the immune system or via a direct effect on oligo-
dendrocytes or neurons through EPA-derived lipid metabolites such as 18-HEPE.
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Background
Multiple Sclerosis (MS) is a chronic inflammatory demy-
elinating disease of the CNS. In the Western world it is 
the main cause of disability in young adults [1] surpassed 
only by trauma, yet its aetiology remains elusive. Recent 
research has acknowledged that even at its onset MS is 
a neurodegenerative disease with irreversible damage to 
axons and neurons [2, 3]. Although the precise mecha-
nism responsible for neuronal loss is not known, the two 
main risk factors for injurious processes are inflamma-
tion and demyelination.
However, recent evidence suggests that the inflamma-
tory response to demyelination is not just a risk factor for 
neuronal loss, but also a necessary condition for remy-
elination [4–6]. It has been shown that inflammation 
enhances remyelination via direct effects on oligoden-
drocyte precursor cells (OPCs) survival, migration and 
differentiation [7, 8]. Also, the presence of myelin debris 
in CNS tissue inhibits remyelination by OPCs [9, 10]. 
Hence the presence of activated macrophages that clear 
this debris is essential for remyelination. Furthermore, 
activated macrophages are also capable of inducing OPCs 
[11, 12]. This Janus-face of inflammation has resulted 
in the distinction between destructive and protective 
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inflammation, where protective inflammation is associ-
ated with enhanced remyelination and reduced neuronal 
loss.
Despite promising initial results, all recently developed 
drugs that tried to address these new findings have been 
unable to stop disease progression or to exert neuropro-
tection or even neuroregeneration [13]. Instead, some of 
the newly developed drugs had adverse side effects [14, 
15] or unexpected drug interactions [16]. There are some 
suggestions that diets which are high in n-3 PUFAs and 
low in saturated fatty acids might stabilize disease in 
MS patients [17, 18]. The rationale behind this approach 
is that n-3 PUFAs via their lipid mediators that are also 
known as resolvins and protectins [19], might modulate 
the destructive autoinflammatory response. However, 
empirical evidence supporting this advice is limited. In 
a Cochrane review of randomized trials of dietary inter-
ventions for MS, Farinotti et al. [20] could not find a sig-
nificant effect of neither omega-6 (n-6) nor n-3 PUFAs on 
disease progression nor relapse rate. By contrast, a recent 
epidemiological study from Australia suggested that the 
risk for central nervous system demyelination is reduced 
in people with a higher intake of omega-3 PUFA [21].
There have been many studies in rodents looking at the 
anti-inflammatory effect of PUFAs in experimental auto-
immune encephalomyelitis (EAE) as an animal model for 
MS [22–24]. However, in all these studies the focus was 
on n-6 PUFAs only. So far only one study [25] has used 
the cuprizone model for the study of the n-3 PUFA effect 
in neural demyelination and remyelination and found 
that a diet high in salmon fish oil protected from demy-
elination and increased remyelination [25].
We set out to confirm the results of this first n-3 PUFA 
cuprizone study in the fat-1 mouse model. This mouse, 
by expressing fat-1 n-3 PUFA desaturase from C. elegans, 
can endogenously synthesize n-3 PUFA from n-6 PUFA 
without using dietary supplementation [26] thus elimi-
nating confounding factors of diet [27]. These mice were 
recently used in several models of neurological disease, 
such as Alzheimer’s disease [28], Parkinson’s disease [29], 
epilepsy [30] and stroke-related brain injury [31]. In all 
models, when compared to wt littermates, they were pro-
tected from neuronal damage. Using the fat-1 model, the 
cuprizone model of demyelination is superior to the EAE 
model, because in EAE the priming and proliferation of 
autoreactive T-cells might already be impeded by the dif-
ferences in n-3 PUFA tissue status.
Methods
Animals
Transgenic fat-1 mice were engineered as previously 
described [26]. They were subsequently backcrossed onto 
a C57BL/6 background at least four times. Generations 
of female heterozygous fat-1 mice and male wt mice 
were then mated to obtain wt and transgenic mice from 
the same offspring. In this study, all transgenic fat-1 
mice used were heterozygous. Animals were kept under 
specific pathogen-free conditions in standard cages and 
were maintained in an air-conditioned atmosphere with 
a controlled 12 h light–dark cycle. They were fed a spe-
cial semi-purified diet (AIN-76A containing 10% corn 
oil) high in n-6 and low in n-3 fatty acids. Sterile drink-
ing water was given ad  libitum. Each cage housed four 
to six weight-matched female mice. Mouse studies were 
approved by the Massachusetts General Hospital Sub-
committee on Research Animal Care (Additional file  1: 
Figure S1).
Mice were divided into a fat-1 group and a wt group 
according to their phenotype. For phenotyping the tip of 
mouse-tails (100 mg) was cut off from six-week-old mice 
and subjected to gas chromatographic analysis. The ratio 
between n-6 PUFAs [arachidonic acid (AA) and gamma-
linolenic acid (GLA n-6)] and n-3 [alpha-linolenic acid 
(ALA), eicosapentaenoic acid (EPA), docosapentaenoic 
acid (DPA n-3) and docosahexaenoic acid (DHA)] was 
determined for each individual mouse to distinguish 
between wt and transgenic phenotypes. Mice that had 
an n-6/n-3 ratio ≤5 were assigned to the fat-1 group and 
those with an n-6/n-3 ratio >10 were assigned to the wt 
group. The analysis of the three most important PUFAs, 
AA, EPA and DHA, are presented in Fig. 1.
Chemically induced demyelination with cuprizone
Six experimental groups were set up to investigate the 
impact of endogenously altered n-3/n-6 PUFA status on 
Fig. 1 Lipid profile in wt and fat-1 mouse-tails. Fatty acid composi-
tion of the tail was analysed using GC. The long-chain PUFAs AA, EPA 
and DHA were included in this comparison. The respective mean 
values and standard errors for wt animals are AA 31.9% (±0.6), EPA 0% 
(±0) and DHA 3.1% (±0.3). For fat-1 animals they are AA 3.5% (±0.7), 
EPA 9.5% (±0.6) and DHA 10.9% (±0.4). There were statistically signifi-
cant differences between all three PUFAs in mouse-tails
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remyelination following cuprizone-induced demyelina-
tion in mice (see Additional file 2: Figure S2 for details). 
Starting at nine weeks of age control animals (four fat-1 
and four wt mice) were maintained on a normal pulver-
ized diet for five weeks, while cuprizone animals received 
a pulverized diet containing 0.2% cuprizone (w/w) 
(Bis(cyclohexanone)oxaldihydrazone, Sigma-Aldrich, 
St. Louis, MO, USA), also for five weeks. Animals in the 
cuprizone demyelination group (seven fat-1 and five wt 
mice) were sacrificed at the end of these five weeks on 
the cuprizone diet and their tissue was used to assess 
whether there were any differences in demyelination 
between wt and fat-1 animals. Animals in the cuprizone 
remyelination group (seven fat-1 and five wt mice) were 
first fed the cuprizone diet for five weeks and were then 
allowed to recover for another two weeks on a normal 
diet. They were then sacrificed in order to see whether 
there were any differences in remyelination between wt 
and fat-1 animals. Animal weight was recorded through-
out the entire experiment.
All animals were sacrificed by anaesthesia with isoflu-
rane (IsoFlo®, Abbott Laboratories, Abbott Park, Illinois, 
USA). Following their sacrifice, animals were transcardi-
ally perfused with ice-cold PBS. Brains and spinal cords 
were then excised and the brain was cut into three parts: 
the rostral 2/3 of the brain were prepared for histology; 
the occipital 1/3 and the cerebellum, as well as the spi-
nal cord, were fresh-frozen and stored at −20 °C for gas 
chromatography (GC) analysis.
Histology
The rostral 2/3 of the brains were first fixated in 4% PFA 
(Arcos Organics, Fairlawn, NJ, USA) at 4 °C for 24 h and 
subsequently quenched in a sucrose gradient (Sigma-
Aldrich, St. Louis, MO, USA) over two days before they 
were fresh-frozen in Shandon M-1 Embedding Matrix® 
(Thermo Fisher Scientific, Waltham, MA, USA) for cry-
osectioning. Coronal brain sections were cut at 10  µm 
thickness corresponding to slice 205 of the Harvard High 
Resolution Mouse Brain Atlas [32]. Sections were then 
air-dried and stored at −20  °C until further processing. 
Luxol Fast Blue staining was used to quantify myelin.
For Luxol Fast Blue (LFB) staining, sections were first 
hydrated in aqua bidest. Next, sections were rinsed in 
70% ethanol and placed in 0.1% LFB (Solvent Blue 38®, 
Sigma-Aldrich, St. Louis, MO, USA) staining solution for 
6 h at 60 °C. Following the 6 h of staining, sections were 
then rinsed in 95% ethanol, followed by aqua bidest. In 
the next step sections were postfixed in 1% lithium car-
bonate solution (Sigma-Aldrich, St. Louis, MO, USA) and 
subsequently rinsed in 70% ethanol and aqua bidest. This 
step was repeated until there was a clear differentiation 
between white and grey matter staining. Sections were 
then counterstained in 0.1% Cresyl Violet acetate solution 
(Sigma-Aldrich, St. Louis, MO, USA). Eventually, sec-
tions were rinsed in aqua bidest followed by 95 and 100% 
ethanol, then xylol and then they were coverslipped.
Stainings were evaluated with a LSM 5 Pascal confo-
cal microscope (Carl Zeiss AG, Oberkochen, Germany). 
Of each brain a photo was taken of the corpus callosum 
at slice 205 of the mouse brain atlas. These photos were 
then analysed using ImageJ software by three blinded 
independent assessments. First, equal volumes (300,000 
square pixels) of corpus callosum were selected. Within 
this volume the area that stained positive for myelin was 
then selected and the size of the myelinated area was 
recorded (Additional file 2: S2).
Gas chromatography
For PUFA analysis, brain or tail tissues frozen in liquid 
nitrogen were ground into powder in liquid nitrogen. The 
powder was subjected to extraction of total lipids and 
fatty acid methylation by heating them at 100 °C for 1 h 
in a solution containing 2.5  ml hexane and 2.5  ml 14% 
boron trifluoride in methanol. Once the samples had 
cooled down to room temperature they were vortexed. 
Next, 1 ml water was added to the solution. In order to 
ensure that the concentration between the aqueous and 
the lipophilic phase was in equilibrium the samples were 
shaken by hand for 4  min. The phases were then sepa-
rated by centrifugation and the lipophilic hexane phase 
containing fatty acid methyl esters was removed and 
dried under nitrogen. The fatty acid methyl ester residues 
were redissolved in 50 µl hexane and transferred into an 
autosampler vial. They were then analysed by GC using a 
fully automated Hewlett Packard 5890 system equipped 
with a flame ionization detector. Peaks of resolved fatty 
acids were identified by comparison with a fatty acid 
standard and the area under those resolved peaks repre-
sented their relative concentrations. The size of the areas 
was measured using a Perkin Elmer M1 integrator.
Liquid chromatography mass spectrometry/mass 
spectrometry (LC MS/MS)
For analysis of monohydroxy lipid metabolites thirty mil-
ligrams ground and frozen brain tissue from wt (n = 7) 
and fat-1 (n  =  4) mice was mixed with methanol and 
internal standard (LTB4-d4) and hydrolysed with 300 μl 
of 10 M sodium hydroxide for 30 min at 60 °C. The solu-
tion was neutralized with 60% acetic acid and pH was 
adjusted to 6.0 with sodium acetate buffer. A solid phase 
extraction was performed with an anion exchange col-
umn (Bond Elute Certify II, Agilent, Santa Clara, CA) as 
described previously [33]. For elution, an n-hexane:ethyl 
acetate extraction mixture 25:75 with 1% acetic acid was 
used. The eluate was evaporated on a heating block at 
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40  °C under a stream of nitrogen to obtain a solid resi-
due. Residues were then dissolved in 70  μl acetonitrile. 
An Agilent 1200 high performance liquid chromatogra-
phy (HPLC) system and a solvent system consisting of 
acetonitrile/0.1% formic acid in water was used. The gra-
dient elution was started with 15% acetonitrile, this was 
increased within 10 min up to 90% and held for 10 min. 
The HPLC system was coupled with an Agilent 6410 Tri-
plequad mass spectrometer with electrospray ionization 
source. Analysis of lipid mediators was performed using 
Multiple Reaction Monitoring in negative mode and con-
verted into an electrical signal by an electron multiplier 
dynode. The resulting signals were identified and quan-
tified with the help of previously analysed standards, all 
from Cayman Chemical (Ann Arbor, MI, USA). Results 
were then analysed using Agilent Technology’s Mass-
Hunter Workstation Software Quantitative Analysis 
B.03.01 and Quantitative Analysis B.02.00.
Monohydroxy lipid metabolites analysed were those 
either enzymatically or non-enzymatically derived from 
the long-chain PUFAs AA, EPA and DHA. In particular, 
we focused on AA-derived 5-, 8-, 9-, 12- and 15-hydrox-
yeicosatetraenoic acid (HETE). Concerning n-3 PUFA-
derived monohydroxy lipid mediators we focused on 
EPA-derived 5-, 8-, 9-, 12-, 15- and 18-hydroxyeicosapen-
taenoic acid (HEPE) and on DHA-derived 4-, 7-, 8-, 10-, 
11-, 13-, 14-, 16-, 17- and 20-hydroxydocosahexaenoic 
acid (HDHA).
Statistical analysis
Statistical analysis of the results was performed in Graph 
Pad Prism 6 (GraphPad Software, Inc., La Jolla, USA) 
calculating the mean values of group sizes  ±  standard 
error of the mean (SEM) and using the Mann–Whit-
ney U test. Statistical significance was set at a level of 
p < 0.05. Whenever asterisks are used to describe levels 
of statistical significance, * stands for 0.05 > p > 0.01, ** 
for 0.01 ≥ p ≥ 0.001 and *** for p < 0.001.
Results
GC was used to analyse the lipid profile of brain tissue 
from wt and fat-1 mice. While lipid profiles of mouse-
tails showed significant differences for the long-chain 
omega-3 PUFA AA, EPA and DHA (Fig. 1), these differ-
ences were significant only for EPA in brain tissue, which 
was detectable only in the fat-1 mice tested (Fig.  2a). 
This was also reflected in the amounts of monohydroxy 
lipid metabolites derived from AA, EPA and DHA: 
While amounts of AA-derived HETEs and DHA-derived 
HDHAs were not significantly different, levels of EPA-
derived HEPEs were significantly higher (Fig. 2b).
More specifically, there were no significant differ-
ences for 8-/9-HETE, as well as 5-HETE, 12-HETE and 
15-HETE, which are derived from 5-, 12-, or 15-lipoxy-
genase action (Fig. 3a). Similarly, differences for the cor-
responding DHA metabolites 4-/7-HDHA, 14-HDHA 
and 17-HDHA were not significantly different between 
wt and fat-1 animals (Fig. 3c). In contrast, while present 
only in much smaller amounts, the corresponding EPA 
derived metabolites were all significantly increased in 
fat-1 mice: Most notably high amounts of 18-HEPE were 
found (Fig. 3b).
Given that 18-HEPE is a pathway marker of anti-
inflammatory and pro-resolution mediators such as 
resolvin E1 and E2 [19], and an anti-inflammatory com-
pound itself [34], we hypothesized that the difference 
between omega-3 PUFA in wt and fat-1 mice—while only 
clearly discernible for EPA and its hydroxy metabolites—
might lead to an anti-inflammatory and/or pro-resolu-
tion phenotype in the context of cerebral inflammation.
In the next step we thus evaluated the effect of cupri-
zone feeding in wt and fat-1 mice. Feeding mice cuprizone 
had a suppressive effect on their metabolism, leading to 
weight loss in wt and fat-1 mice (−11 and −13%, respec-
tively). There was no significant difference between those 
two groups indicating that expression of the fat-1 gene 
and the changed n-3 PUFA tissue content in fat-1 mice 
did not interfere with the uptake and toxic metabolic 
effect of cuprizone in this study (Additional file 3: S3).
The cuprizone feeding model allows to study demyeli-
nation as well as remyelination by analysing representa-
tive brain slides either directly after cuprizone feeding or 
later in the recovery period. Mice were sacrificed at two 
time points to evaluate the effect of different n-3 PUFA 
status on demyelination and remyelination and Luxol 
Fast Blue (LFB) staining was used to quantify myelin 
(Fig. 4). The mean volumes that stained positive for mye-
lin were quantified as described in “Methods” (see also 
Additional file 3: S3).
Next, the mean volume and the SEM were calculated 
for each treatment group (Fig. 5). For the control groups, 
there were no significant differences between wt ani-
mals and fat-1 animals (wt control: mean 274,257 pixels2 
(±4078), fat-1 control: mean 287,886 pixels2 (±7219), 
p = 0.23). This was true also for the demyelination group 
where wt animals had a mean volume of myelin in their 
corpus callosum that was similar to the values observed 
in fat-1 animals (wt demyelination 104,459 pixels2 
(±14,398), fat-1 demyelination 121,534 pixels2 (±18,059, 
p = 0.51). At the same time the cuprizone-treated groups 
had both significantly lower myelin staining values than 
the control groups (p < 0.001). In the remyelination phase 
there was a close miss of statistical significance between 
remyelinated wt animals with a lower mean volume in wt 
animals (156,414 ± 25,717) versus higher values in fat-1 
animals (239,981 ± 24,764) (p = 0.07).
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Fig. 2 Long-chain PUFAs and their metabolites in brain tissue of wt and fat-1 mice. a Fatty acid composition in brain tissue of wt and fat-1 mice 
were analysed using GC. The only significant difference in n-3 PUFAs in wt and fat-1 brain tissue was observed for EPA (EPA in wt cerebella 0 ± 0; 
EPA in fat-1 cerebella 34.6 ± 19.5; p = 0.003), which was detectable only in the fat-1 mice tested. AA and DHA levels in wt and fat-1 mice were wt: 
2549 ± 203, 4769 ± 539; fat-1: 2418 ± 169, 4904 ± 398 respectively. b Lipid metabolite profiles in brain tissue of wt and fat-1 mice were analysed 
using LC MS/MS. Similarly, levels of EPA-derived total HEPEs were significantly higher in fat-1 animals. Levels of AA-derived HETEs and DHA-derived 
HDHAs levels were similar among wt and fat-1 animals
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Fig. 3 Comparison of lipid metabolite profiles in brain tissue of wt and fat-1 mice. a Levels of AA-derived HETEs were analysed using LC MS/MS. 
They were relatively similar among wt and fat-1 animals (presented as mean values and SEM). b The only significant difference in lipid metabolites 
between wt and fat-1 brain tissue was observed for EPA-derived monohydroxy metabolites. Levels of EPA-derived HEPEs were significantly higher in 
fat-1 animals with particularly high amounts of anti-inflammatory 18-HEPE. c Concerning DHA-derived HDHAs, levels were also relatively similar in 
the brain tissue of wt and fat-1 mice with no significant differences among any of the DHA-derived metabolites
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Discussion
Comparing the lipid profile of tails and brain between 
healthy wt and fat-1 mice, we found only small differ-
ences in the FA profiles between wt and fat-1 mouse 
brain tissue (Fig. 2a). A possible explanation for this dif-
ference is that in the CNS DHA might play such a cru-
cial role, so that it is enriched here even in the context 
of low n-3 PUFA supplementation. This has been shown 
previously by Jeffrey et al. [35] for DHA in retinal cells. 
Since then it has been suggested that a similar princi-
ple might regulate trafficking of certain n-3 PUFAs to 
the brain [36]. In rats that are depleted of dietary n-3 
PUFAs there is an increase in DHA synthesis from ALA 
in the liver [37, 38]. Hence one possible scenario would 
be that in DHA-depleted dietary states there is pref-
erential trafficking of liver-derived DHA to the brain, 
amongst others through lipoprotein receptors [37].
While the total difference in DHA was small, there 
was, however, a significant difference of the amounts 
of EPA present, leading to increased amounts of poten-
tially anti-inflammatory and anti-fibrotic 18-HEPE [39] 
in fat-1 brains. At the same time, levels of anti-inflam-
matory DHA metabolites, while much higher than the 
EPA metabolites, were unchanged between wt and fat-1 
groups (Fig. 3).
In the cuprizone feeding model of demyelination dam-
age in the brain there was no difference in the amount of 
demyelination between fat-1 and the wt animals, possi-
bly reflecting the fact that additional n-3 PUFA synthesis 
in fat-1 mice was not able to confer an additional protec-
tive effect on top of the already high n-3 PUFA levels in 
wt brains. However, we saw improved remyelination in 
fat-1 mice; but this difference missed statistical signifi-
cance at p = 0.07. Given our relatively small sample size 
with an average group size of 5 animals statistical sig-
nificance might be reached by increasing case numbers. 
Thus the data presented here suggest that an increased 
n-3 PUFA tissue status might lead to a mild beneficial 
effect of n-3 PUFAs on in  vivo CNS remyelination in 
mice.
Our data are only partially consistent with previous 
data on the effect of n-3 PUFA in the cuprizone model of 
demyelination. Torkildsen et al. [25] had tested the effect 
of diets with different compositions of PUFAs on de- and 
remyelination in C57/BL6 mice with cuprizone-induced 
demyelination. They found that mice receiving a salmon-
based diet suffered less demyelination in response to 
cuprizone than those on a cod liver or soybean oil diet 
and saw no differences in the degree of remyelination. 
The three different diets that were tested in Torkildsen’s 
study differed in the lipid source of their 4% lipid content. 
One diet contained its lipids from salmon fillets with an 
unknown n-3 PUFA content, the other from cod liver 
oil (with approx. 24 g n-3 PUFAs/100 ml cod liver oil, of 
which 12 g DHA and 8 g EPA) and the third from soy-
bean oil (with approx. 50 g linoleic acid/100 ml soybean 
oil). Mice were started on one of these diets at four weeks 
of age, i.e. 4 weeks prior to cuprizone feeding. However, 
this study lacked direct PUFA measurements in brain 
tissue.
An important point of our study is that we quantified 
actual differences in PUFA tissue status both in the tail 
and in the CNS. Interestingly, despite small differences 
in the FA profile of wt and fat-1 animal brains, we were 
Fig. 4 Histological Luxol Fast Blue staining for myelin was performed on cryosections of mice’s corpus callosum on slices corresponding to slice 
205 of the Harvard High Resolution Mouse Brain Atlas. Pictures were taken at a magnification of ×10
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able to see differences in the degree of remyelination 
between these groups. One possibility that would explain 
this finding is that despite similar AA and DHA pro-
files in the brain, there might be differences in the EPA-
derived lipid mediators that are produced in the course of 
cuprizone-induced de- and remyelination. In this study 
we only established baseline measurements of hydroxyl 
metabolites, in which there was no difference for the 
DHA-derived metabolites but significant differences for 
the EPA-derived 18-HEPE.
Our finding of increased levels of EPA-derived 
18-HEPE in the brain of fat-1 versus wt mice could 
be interpreted in the light of other recent studies of 
18-HEPE. Endo et  al. [40] showed that in fat-1 mice 
there is a selective enrichment of EPA in fat-1 transgenic 
bone marrow cells and EPA-metabolite 18-HEPE in fat-
1 transgenic macrophages. Bone marrow transplantation 
experiments revealed that an 18-HEPE-rich environment 
through transplantation of fat-1 transgenic bone mar-
row prevented macrophage-mediated cardiac remodel-
ling via cardiac fibroblasts. This anti-fibrotic effect of 
18-HEPE on cardiac fibroblasts was reproduced in  vivo 
and in vitro. Similarly, in a study on murine macrophages 
18-HEPE was able to significantly decrease macrophages’ 
TNF-alpha formation in vitro [33].
While there might be a tight regulation of DHA levels 
in the CNS, differences in EPA levels might thus lead to 
significant changes in anti-inflammatory lipid metabo-
lites in the brain. Therefore, a possible explanation for the 
protective effect of an n-3 PUFA-enriched tissue status 
in CNS demyelinating disease could be a difference par-
ticularly in EPA-derived metabolites such as 18-HEPE. 
Based on the data from Torkildsen et al. [25], these could 
affect mainly macrophage function, although further 
experiments might be necessary to assess also the role of 
astrocytes in this model. Future studies will now have to 
assess the activity and function of macrophages/micro-
glia found at the sites of CNS injury in the cuprizone 
model and to understand the effect of EPA on activity of 
these cells.
As compared to our analysis in mice, a meta-analysis 
by Farinotti et  al. [20] has concluded that n-3 PUFAs 
did not have an effect on 292 patients with relapsing 
remitting MS. However, there are several arguments 
why a positive effect of n-3 PUFAs on remyelination in 
patients suffering from MS might not have shown up in 
the two studies that were evaluated by Farinotti and col-
leagues [13, 41]: Patients in both studies received EPA at 
1.71 and 1.98 g/d and DHA at 1.14 and 1.32 g/d, (which 
is well above the general dietary recommendations by 
most nutritional guidelines). Both studies found that 
there was a rise in EPA serum level in patients receiving 
fish oil compared to olive oil. While Weinstock-Guttman 
et al. [41] in their 1-year study found that EPA levels at 
6 and 9 months correlated with disability at 12 months, 
Bates et  al. [13] found a non-significant trend between 
higher EPA and DHA levels due to fish oil supplements 
and lower disability in MS patients following two years 
of dietary intervention. Only Bates et  al. [13] checked 
for effective uptake of PUFAs into adipose tissue. While 
there was a significant increase in EPA and DHA in adi-
pose tissue as early as 6 months after supplementation, 
most of the change was only seen at 2  years on thera-
peutic intervention. Hence, it would be essential in any 
interventional study to check for effective uptake of n-3 
PUFAs into relevant tissue and to choose an appropriate 
time frame accordingly. The data from Bates et  al. [13] 
suggests that the time frame that was chosen in those 
studies might have been too short. Also, it is necessary 
to define what the relevant tissue is, i.e. whether differ-
ences in lipid profiles in the CNS, in adipose tissue or 
in immune cells confer those potential benefits. Next, 
a recent epidemiological study from Australia with 267 
cases and 517 controls showed a reduced risk of CNS 
demyelination with higher intake of omega-3 PUFA [21]. 
Furthermore, there is the possibility that isolated n-3 
PUFA supplementation might not exert the same ben-
efit as n-3 PUFAs derived from natural nutrition. The 
data from Torkildsen et al. suggests that salmon-derived 
n-3 PUFA might be superior to cod-liver oil [24]. Given 
these limitations, and as concluded by Farinotti et  al. 
[20], future studies will be necessary to settle the ques-
tion of an n-3 PUFA effect in MS. This underscores that 
the topic of n-3 PUFA supplementation in MS warrants 
further investigation.
Given that our observation of increased remyelina-
tion due to increased n-3 PUFA tissue content nar-
rowly missed significance, future mouse studies are 
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Fig. 5 Degree of myelination in the corpus callosum. At a level cor-
responding to slice 205 of the Harvard High Resolution Mouse Brain 
Atlas, an area of 300,000 square pixels of corpus callosum tissue was 
selected. Within this area, the area that stained positive for myelin was 
selected and quantified in square pixels. From these, mean values 
(±SEM) were calculated for each treatment group
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also warranted to further establish this effect in a larger 
cohort of mice in the cuprizone model, as well as in other 
experimental MS models such as EAE.
Conclusion
In the present study using fat-1 mice endogenously form-
ing n-3 PUFA we found a trend towards increased CNS 
remyelination after cuprizone damage in the context of 
higher EPA levels in the brain. The differences in remy-
elination—in the face of CNS lipid profiles differing only 
in EPA levels and not in DHA levels—might be due to 
EPA-derived metabolites such as 18-HEPE, for which 
anti-inflammatory and anti-fibrotic effects have been 
described. While DHA is more abundant in the CNS, this 
finding puts an emphasis on the possible role of EPA and 
its metabolites in CNS remyelination.
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